Statistics for A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)
Total visits
| views | |
|---|---|
| A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302) | 2 |
Total visits per month
| views | |
|---|---|
| May 2024 | 0 |
| June 2024 | 0 |
| July 2024 | 2 |
| August 2024 | 0 |
| September 2024 | 0 |
| October 2024 | 0 |
| November 2024 | 0 |
File Visits
| views | |
|---|---|
| 12885_2023_Article_10971.pdf | 3 |